Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Non-Current Assets: 2013-2025

Historic Other Non-Current Assets for Theravance Biopharma (TBPH) over the last 11 years, with Sep 2025 value amounting to $25.2 million.

  • Theravance Biopharma's Other Non-Current Assets rose 237.36% to $25.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.2 million, marking a year-over-year increase of 237.36%. This contributed to the annual value of $12.3 million for FY2024, which is 52.30% up from last year.
  • Latest data reveals that Theravance Biopharma reported Other Non-Current Assets of $25.2 million as of Q3 2025, which was down 2.25% from $25.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Other Non-Current Assets ranged from a high of $25.8 million in Q2 2025 and a low of $1.3 million during Q2 2021.
  • For the 3-year period, Theravance Biopharma's Other Non-Current Assets averaged around $12.9 million, with its median value being $11.6 million (2023).
  • As far as peak fluctuations go, Theravance Biopharma's Other Non-Current Assets spiked by 295.80% in 2021, and later plummeted by 34.71% in 2024.
  • Over the past 5 years, Theravance Biopharma's Other Non-Current Assets (Quarterly) stood at $3.2 million in 2021, then spiked by 113.72% to $6.9 million in 2022, then grew by 16.93% to $8.1 million in 2023, then skyrocketed by 52.30% to $12.3 million in 2024, then spiked by 237.36% to $25.2 million in 2025.
  • Its Other Non-Current Assets stands at $25.2 million for Q3 2025, versus $25.8 million for Q2 2025 and $13.8 million for Q1 2025.